A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Eligibility Criteria

• * Have either measurable or evaluable disease using standard techniques by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
• * The participant has a Lansky (\<16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50.
• * Participants must have discontinued all previous treatments for cancer or investigational agents greater than or equal to (≥)7 days after the last dose and must have recovered from clinically significant side effects.
• * The participant has adequate hematologic and organ function.
• * Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to first dose.
• * Both female and male participants of childbearing potential must agree to use highly effective contraceptive precautions during the trial and for at least 3 months following the last dose of study drug.
• * Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that, in the opinion of the investigator, could cause unacceptable safety risks or compromise compliance with the protocol.
• * Participants who have active infections requiring therapy.
• * Participants who have had allogeneic bone marrow or solid organ transplant.
• * Participants who have had, or are planning to have, certain invasive procedures.
• * Female participants who are pregnant or breastfeeding.